Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05046080 · ClinicalTrials.gov registry record
Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix
A clinical trial of Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 70
- Enrollment target
- 1
- Study location
NCT05046080: Recruiting study of Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, sponsored by M.D. Anderson Cancer Center.
NCT05046080 is a study of Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 70 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05046080, a study of Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. This study may help researchers learn more about the molecular profile of cervical clear cell carcinoma.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Electronic Health Record Review
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-08-06 |
| Est. Completion | 2026-09-29 |
What NCT05046080 shows while recruiting
NCT05046080 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 70 participants, a relatively small participant target.
The record links to 1 condition, with Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT05046080 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05046080 about?
NCT05046080 is a clinical study titled "Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix". This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. This study may help researchers learn more about the molecular profile of cervical clear cell carcinoma.
What is the current status of trial NCT05046080?
This trial is currently recruiting. The enrollment target is 70 participants. The study started on 2021-08-06. Estimated completion is 2026-09-29.
What conditions does trial NCT05046080 study?
This clinical trial studies the following conditions: Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type.
What interventions are being tested in trial NCT05046080?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Electronic Health Record Review (OTHER).
Who is sponsoring clinical trial NCT05046080?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05046080 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI